Study Type
|
Title of Study
|
| RHEUMATOID ARTHRITIS |
| Treatment/Interventional |
TARGET: To compare the effects on vascular inflammation of TNFi + MTX versus triple therapy in subjects with RA who are inadequate responders to MTX using FDG PET/CT as a tool for detecting vascular (arterial) inflammation.
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact 310-206-4007
|
| Observational |
Longitudinal Cardiovascular Risk Study of Patients with Rheumatoid Arthritis
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact 310-206-4007
|
| Treatment |
StopRA: Study to determine if hydroxychloroquine is safe and effective for the prevention of future onset of RA in people with elevated anti-CCP levels.
|
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461
|
| Treatment |
CANNABIDIOL: Therapeutic Response of Cannabidiol in Rheumatoid Arthritis |
Principal Investigators
Veena K. Ranganath, MD, MS, RhMSUS
For more information, contact Nicolette 310-825-9956
|
| Treatment |
CANNABIS: Cannabis Anonymous Questionnaire in UCLA Rheumatology Patients. |
Principal Investigators
Veena K. Ranganath, MD, MS, RhMSUS
For more information, contact Nicolette 310-825-9956
|
| Treatment |
ACTHAR: Use of ACTHAR in Rheumatoid Arthritis Related Flares. |
Principal Investigators
Veena K. Ranganath, MD, MS, RhMSUS
For more information, contact Nicolette 310-825-9956
|
|
UPCOMING STUDIES
|
| Treatment |
RA-PROPR
|
Principal Investigators
Veena K. Ranganath, MD, MS, RhMSUS
For more information, contact Nicolette 310-825-9956
|
| SYSTEMIC LUPUS ERYTHEMATOSIS |
| Observational |
Precise: Looking for inpatient active lupus patients upon initial admission (prior to steroids) to follow longitudinally for disease activity. |
Principal Investigators
Jennifer King, MD, PhD
For more information contact Samya 310-825-2548 |
| Treatment |
ALE09: Study to evaluate the efficacy, safety, and tolerability of lenabasum (synthetic cannabinoid) in decreasing pain associated with arthritis or tendonitis in lupus patients. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| Treatment |
Eli Lilly JAHZ: Study to determine the effect of baricitinib and standard-of-care therapy on lupus disease activity. |
Principal Investigators
Jennifer Grossman, MD
For more information contact Julia 310-825-6461 |
| Observational |
Pro-inflammatory HDL Cholesterol: Evaluating biomarkers of risk for atherosclerosis in lupus. Involves a one-time blood draw. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Lucas 310-825-2598 |
| Treatment |
IDEAL: Evaluating the value of educational information about the risks and benefits of lupus medications. Implementation of the DEcision-Aid for Lupus in practice settings for shared decision-making. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| Treatment |
BMS PAISLEY: A study to evaluate the efficacy and safety of BMS-986165 in improving renal function in lupus nephritis patients who do not adequately respond to mycophenolate mofetil (MMF). |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
|
UPCOMING STUDIES
|
| Observational |
GSK Belimumab in Early Lupus: A study to evaluate the effects of belimumab in patients recently diagnosed with lupus. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| Treatment |
Amgen AMG570: A study evaluating the safety and efficacy AMG 570 in lupus patients. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| SCLERODERMA |
| Treatment |
BRAVOS ITN075AI: Study of an Investigational Drug, Brentuximab Vedotin, for Diffuse Cutaneous Systemic Sclerosis |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis Systemic Sclerosis-Associated Pulmonary Arterial Hypertension |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
CORBUS JBT101-SSc-002: A study to evaluate efficacy and safety of Lenabasum in diffuse cutaneous Systemic Sclerosis |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational (Long-Term Follow-Up) |
ASSET Long Term Follow-Up: A long term follow-up on ASSET: A study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational |
GRASP: Genome Research in African American Scleroderma Patients (GRASP) |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational |
SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) cohort collecting data on a regular basis related to problems likely to be important for many people living with scleroderma |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational |
PI-Initiated: A study to define the differences in IMMUNE RESPONSES in skin from patients with an autoimmune or inflammatory condition |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
Scleroderma Lung Study III: Mycophenolate vs. Mycophenolate + Pirfenidone for systemic sclerosis-interstitial lung disease: This study compares two treatment regimens for systemic sclerosis-related lung disease: mycophenolate alone versus mycophenolate plus pirfenidone, an anti-fibrotic medication. This study is ongoing but currently closed to enrollment. |
Co-Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| Observational |
Systemic Sclerosis Microbiome study: This study examines whether the gut microbiome contributes to the pathogenesis (cause) of systemic sclerosis. All patients with systemic sclerosis are eligible to participate in this study. |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| Observational |
The Gut Microbiome as a Screening Tool for ILD in Systemic Sclerosis: This study determines whether systemic sclerosis patients with interstitial lung disease (pulmonary fibrosis) have unique features of their gut microbiome. This study also seeks to determine whether the gut microbiome can be used to screen for the presence of interstitial lung disease in early systemic sclerosis. |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213 |
| Observational |
Biomarkers to Predict Treatment Response in Systemic Sclerosis-Interstitial Lung Disease: This is an NIH-sponsored study to discover novel biomarkers that predict response to therapy and outcomes in patients with systemic sclerosis-related interstitial lung disease. The outcomes of this research will allow us to develop personalized treatment plans for patients. All patients with systemic sclerosis-related interstitial lung disease are eligible to participate. |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| Observational |
CURESSC - Consortium of Universities to REsearch Scleroderma in Southern California: This study seeks to understand the genetics of systemic sclerosis and how changes in the blood vessels and fibroblasts (cells involved in fibrosis) contribute to skin disease in systemic sclerosis. The results of this study may reveal new treatment targets. Any patient with diffuse systemic sclerosis is eligible to participate. |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Observational |
PET study of 68Ga-FAPi-46 in patients with interstitial lung disease: An exploratory biodistribution study with histopathology validation: This study aims to explore a novel radiographic assessment measure of fibroblast activation in patients with interstitial lung disease. The results may help us better understand the cause of interstitial lung disease and help us in making informed treatment decisions for patients. All patients with interstitial lung disease are eligible to participate. |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| Observational |
Scleroderma Clinical Trial Consortium: This study examines the gut microbiome of patients with systemic sclerosis from across the world to determine the impact of diet and environment on microbial composition in systemic sclerosis. This study will also evaluate whether the microbiome can serve as a marker of disease activity in systemic sclerosis. |
Co-Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| Treatment |
Kadmon KD025-209: A placebo-controlled study to evaluate the efficacy and safety of KD025 (ROCK2 inhibitor) in subjects with diffuse cutaneous systemic sclerosis. This is a new investigational therapy for patients with systemic sclerosis. Patients can continue to take their regular medications while they participate in this study.
|
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| Treatment |
Kadmon KD025-215: A study to evaluate the efficacy and safety of Belumosudil in subjects with diffuse cutaneous systemic sclerosis. This is a new investigational therapy for patients with systemic sclerosis. In this open-label study, all patients will have the opportunity to receive the investigational therapy. Patients can continue to take their regular medications while they participate in this study.
|
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| Treatment |
Galapagos GLPG1690: A study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 (ATX inhibitor) |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
Horizon: A study to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patients with diffuse cutaneous systemic sclerosis. This is a new investigational therapy for patients with systemic sclerosis. Patients can continue to take their regular medications while they participate in this study. |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-794-6213
|
| UPCOMING STUDIES |
| Treatment |
Eicos ES-301: A study evaluating the safety and efficacy of IV Iloprost in subjects with systemic sclerosis experiencing symptomatic digital ischemic episodes |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
IgPro10_2001: Study to evaluate the efficacy and safety of IgPro10 (intravenous immunoglobulin, Privigen®) for the treatment of adults with Systemic Sclerosis
|
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
PSORIATIC ARTHRITIS & ANKYLOSING SPONDYLITIS
|
| Treatment |
Novartis CAIN457F2354: A study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis
|
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| MYOSITIS |
| Observational |
Longitudinal Cohort Study of Patients with Idiopathic Inflammatory Myopathies
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact 310-206-4007
|
| Treatment/Interventional |
CSL Behring: A study to evaluate the efficacy safety, and pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) in adults with dermatomyositis (DM)
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact 310-206-4007
|
| UPCOMING STUDIES |
| Treatment/Interventional |
Pfizer C0251002: A study to evaluate the efficacy, safety, and tolerability of Pf-06823859 in adult subjects with dermatomyositis (DM)
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact 310-206-4007
|
| Treatment/Interventional |
Alexion ALXN1210-DM-310: A multicenter study to evaluate the efficacy and safety of Ravulizumab in adult participants with dermatomyositis (DM) |
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact 310-206-4007
|
| SJOGREN'S SYNDROME |
| Observational |
NGS Sjogren’s: Looking for primary Sjogren’s patients, both seropositive SSA+ or seronegative; especially with parotid swelling
|
Principal Investigator
Jennifer King, MD
For more information, contact Samya 310-825-2548
|
| VASCULITIS |
|
No Studies at this time |
|
| GOUT |
|
No Studies at this time |
|
| CONNECTIVE TISSUE DISEASE-INTERSTITIAL LUNG DISEASE (CTD-ILD) |
| Observational |
CTD-ILD Registry: Any patient with a CTD-ILD |
Principal Investigators
Elizabeth Volkmann, MD, MS
For more information contact Paul or Eileen 310-794-2466 |
